Investors

Media

Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company.

For an e-mail response to questions about Regeneron, please contact us at media@regeneron.com.



Upcoming Events

Feb 10, 2015
8:30 AM ET
Webcast Regeneron Pharmaceuticals Q4 2014 Earnings Conference Call


View all releases Recent Press Releases

Jan 26, 2015 Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA
Jan 23, 2015 EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union
Jan 12, 2015 Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA
Jan 9, 2015 Regeneron to Report Fourth Quarter and Full Year 2014 Financial and Operating Results and Host Conference Call and Webcast on February 10, 2015
Jan 9, 2015 Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia
Dec 19, 2014 Regeneron Announces Presentation and Panel Discussion at the 33rd Annual J.P. Morgan Healthcare Conference
Dec 15, 2014 Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol
Dec 1, 2014 EYLEA® (aflibercept) Injection Accepted for Priority Review by FDA for Diabetic Retinopathy in Patients with Diabetic Macular Edema
Nov 20, 2014 Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis
Nov 19, 2014 Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol


Close
Form content here please :)